In particular, weight loss induced by GLP-1 RAs has been associated with significant improvement in debilitating headaches, especially in conditions such as idiopathic intracranial hypertension (IIH) and migraine, both of which are known to be exacerbated by obesity and its associated systemic inflammation.10Furthermore, the anti-inflammatory properties and cytokine-modulating effects of GLP-1 RAs appear to contribute to pain regulation, implying a supplementary therapeutic modality.11 Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.